MétaCan
Menu
Back to cohort
Record W4411489613 · doi:10.1158/1078-0432.ccr-24-3912

<i>ERBB2</i> /HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

2025· article· en· W4411489613 on OpenAlexafffund
Gillian Vandekerkhove, Andrew J. Murtha, David C. Müller, Maria Stephenson, Kimia Rostin, Aslı D. Munzur, Carlos Vasquez-Rios, Jussi Nikkola, Joonatan Sipola, Matti Annala, Cameron Herberts, Emily Fung, Jaskirat Atwal, Sadeem Al-Subaie, Karan Parekh, Cecily Q. Bernales, Gráinne Donnellan, Daygen L. Finch, Krista Noonan, Jenny J. Ko, Güliz Özgün, Lucia Nappi, Christian Kollmannsberger, Jean‐Michel Lavoie, Sunil Parimi, Tilman Todenhöfer, Piet Ost, Gang Wang, Peter C. Black, Corinne Maurice‐Dror, Kim N., Bernhard J. Eigl, Alexander W. Wyatt

Bibliographic record

VenueClinical Cancer Research · 2025
Typearticle
Languageen
FieldMedicine
TopicBladder and Urothelial Cancer Treatments
Canadian institutionsCanada's Michael Smith Genome Sciences CentreAbbotsford Veterinary ClinicSpinal Cord Injury BCBC Cancer AgencyKelowna General HospitalUniversity of British Columbia
FundersCanadian Institutes of Health ResearchBC Cancer FoundationBladder Cancer Advocacy Network
KeywordsGenotypeImmunohistochemistryBiologyCancerDNA sequencingTumour heterogeneityCancer researchBiomarkerFluorescence in situ hybridizationPathologyDNAMedicineGeneGeneticsImmunology

Abstract

fetched live from OpenAlex

PURPOSE: HER2 targeting is increasingly relevant in metastatic urothelial cancer (mUC) because of emerging antibody-drug conjugates, in which assessment of tumor HER2/ERBB2 status could aid interpretation of ongoing trials. We evaluated whether precise ERBB2 genotype can be determined from mUC ctDNA and the relationship with tissue status. EXPERIMENTAL DESIGN: ERBB2 genotype was determined through targeted sequencing of longitudinal samples from 226 patients with mUC. Heterogeneity was evaluated across ctDNA and metachronous tumor tissue ERBB2 genotype and compared with HER2 IHC. RESULTS: Activating ERBB2 mutation and/or amplification was identified in 16% and 29% of patients by ctDNA and tissue sequencing, respectively. Alternatively, 55% of tissue samples were HER2 IHC positive. Agreement between HER2 IHC and ERBB2 genotype (by either ctDNA or tissue) was 64%, in contrast to 87% between patient-matched ctDNA and tissue genotypes. Across serial samples, genotype and IHC revealed marked heterogeneity in ERBB2 status. Factors linked with heterogeneity included ERBB2 amplifications on extrachromosomal DNA, detected through whole-genome sequencing of ctDNA and FISH, and subclonal ERBB2 mutations, which were evident in half of ctDNA and one-third of tissue samples. CONCLUSIONS: We report a combined analysis of HER2 IHC and ERBB2 genotype in mUC ctDNA and archival tissue, revealing high spatiotemporal heterogeneity. Our data suggest that sole reliance on DNA- or protein-based HER2 assessment is insufficient to capture nuanced genomic indicators of HER2 pathway reliance and support a role for ctDNA alongside existing methods for characterizing HER2/ERBB2 status during biomarker development in mUC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.112
GPT teacher head0.506
Teacher spread0.394 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueClinical Cancer ResearchSame topicBladder and Urothelial Cancer TreatmentsFrench-language works237,207